Micardis (Telmisartan)

Telmisartan selectively blocks the AT1 receptor for angiotensin II, preventing vasoconstriction, aldosterone release, and sympathetic activation. This results in relaxed blood vessels, reduced peripheral resistance, and lower blood pressure.

The appropriate dose of Micardis is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any concomitant conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Telmisartan is generally contraindicated in pregnancy because it can affect fetal renal development. It is also not recommended while breastfeeding, as it may pass into breast milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatments with their physician.

To place an order, submit an enquiry on the Micardis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, telmisartan offers a similar blood‑pressure‑lowering effect but with a lower incidence of cough. Unlike calcium‑channel blockers, it directly targets the renin‑angiotensin system, providing additional benefits such as modest metabolic effects. Choice of therapy depends on patient profile and tolerability.

Micardis tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Micardis is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious risks include angioedema, which can affect the face, lips, tongue or airway, and severe hyperkalemia that may cause cardiac arrhythmias. Renal impairment and marked hypotension are also important concerns, especially in patients with pre‑existing kidney disease or volume depletion.

Micardis should be avoided in patients with known hypersensitivity to telmisartan or any ARB component, in those with severe hepatic impairment, and in patients taking aliskiren who have diabetes. Caution is also advised for individuals with significant renal dysfunction or electrolyte abnormalities.